Humacyte Hires SVP of Business Development with $660M Deal Track Record
Humacyte has appointed Rick McElheny as Senior Vice President of Business Development to drive corporate collaborations across its regenerative medicine pipeline. McElheny’s 15+ years in alliance management include overseeing the $660 million Vidara sale and $250 million Clearside deals, positioning him to accelerate commercialization of Symvess® and ATEV therapies.
1. Leadership Appointment
Humacyte appointed Rick McElheny as Senior Vice President of Business Development to expand corporate collaborations across its regenerative medicine pipeline.
2. McElheny’s Industry Experience
McElheny brings over 15 years of alliance management experience, including overseeing the $660 million sale of Vidara Therapeutics and $250 million in Clearside out-licensing transactions.
3. Pipeline and Regulatory Status
Humacyte’s platform includes Symvess® and acellular tissue engineered vessels (ATEVs) with FDA approval for vascular trauma and ongoing trials in hemodialysis access and peripheral artery disease, plus preclinical programs in coronary bypass and Type 1 diabetes.
4. Strategic Growth Outlook
McElheny will target partnerships that accelerate commercialization of ATEV therapies and Symvess®, leveraging his track record to unlock new licensing and M&A opportunities globally.